Arvada

Arvada Therapeutics is a biotechnology company working to develop innovative large-molecule therapeutics for a rare cardiac arrhythmic syndrome known as Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D).

Founder and CEO, Dr. Shi Yin Foo, brings over 20 years of experience as a practicing physician and has held executive roles at Cardioxyl Pharmaceuticals, Cydan Therapeutics, Imara Therapeutics and Tiburio Therapeutics.